Clinical predictors of mortality and cause of death in lymphangioleiomyomatosis: A population-based registry

Lung

Volumn 191, Issue 1, 2013, Pages 35-42

  Oprescu, N ^a   McCormack, F X ^a   Byrnes, S ^b   Kinder, B W ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b The LAM Foundation   (United States)

Author keywords

Cystic lung disease; Epidemiology; Lymphangioleiomyomatosis; Survival

Indexed keywords

ESTROGEN; LEUPRORELIN; PROGESTERONE;

ADULT; ANGIOMYOLIPOMA; ARTICLE; BIRTH; CAUSE OF DEATH; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DISEASE REGISTRY; DISEASE SEVERITY; FEMALE; HORMONAL THERAPY; HUMAN; LUNG TRANSPLANTATION; LYMPHANGIOLEIOMYOMATOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; ONSET AGE; OVARIECTOMY; OXYGEN THERAPY; PNEUMOTHORAX; PREDICTION; PREGNANCY; PRIORITY JOURNAL; PROGNOSIS; QUESTIONNAIRE; RACE; RESIDENT; RETROSPECTIVE STUDY; SMOKING; SURVIVAL TIME; TUBEROUS SCLEROSIS; UNITED STATES;

ADULT; AGE FACTORS; ANGIOMYOLIPOMA; CAUSE OF DEATH; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHANGIOLEIOMYOMATOSIS; MIDDLE AGED; OXYGEN; QUESTIONNAIRES; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; UNITED STATES;

EID: 84873093155     PISSN: 03412040     EISSN: 14321750     Source Type: Journal    
DOI: 10.1007/s00408-012-9419-3     Document Type: Article

References (26)

1. Juvet SC, McCormack FX, Kwiatkowski DJ, Downey GP (2007) Molecular pathogenesis of lymphangioleiomyomatosis: lessons learned from orphans. Am J Respir Cell Mol Biol 36(4):398-408
2. Ryu JH, Moss J, Beck GJ et al (2006) The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment. Am J Respir Crit Care Med 173(1):105-111
3. Crino PB, Nathanson KL, Henske EP (2006) The tuberous sclerosis complex. N Engl J Med 355(13):1345-1356
4. McCormack FX, Inoue Y, Moss J et al (2011) Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 364(17):1595-1606
5. O'Callaghan FJ, Noakes MJ, Martyn CN, Osborne JP (2004) An epidemiological study of renal pathology in tuberous sclerosis complex. BJU Int 94(6):853-857
6. Costello LC, Hartman TE, Ryu JH (2000) High frequency of pulmonary lymphangioleiomyomatosis in women with tuberous sclerosis complex. Mayo Clin Proc 75(6):591-594
7. Franz DN, Bissler JJ, McCormack FX (2010) Tuberous sclerosis complex: neurological, renal and pulmonary manifestations. Neuropediatrics 41(5):199-208
8. McCormack FX (2008) Lymphangioleiomyomatosis: a clinical update. Chest 133(2):507-516
9. Almoosa KF, Ryu JH, Mendez J et al (2006) Management of pneumothorax in lymphangioleiomyomatosis: effects on recurrence and lung transplantation complications. Chest 129(5):1274-1281
10. Corrin B, Liebow AA, Friedman PJ (1975) Pulmonary lymphangiomyomatosis: a review. Am J Pathol 79(2):348-366
11. Silverstein EF, Ellis K, Wolffe M, Jaretzki A (1974) Pulmonary lymphangiomyomatosis. Am J Radiol 120:832-850
12. Johnson SR, Whale CI, Hubbard RB et al (2004) Survival and disease progression in UK patients with lymphangioleiomyomatosis. Thorax 59(9):800-803
13. Urban T, Lazor R, Lacronique J et al (1999) Pulmonary lymphangioleiomyomatosis. A study of 69 patients. Groupe d'Etudes et de Recherche sur les Maladies "Orphelines" Pulmonaires (GERM"O"P). Medicine (Baltimore) 78(5):321-337
14. Matsui K, Beasley MB, Nelson WK et al (2001) Prognostic significance of pulmonary lymphangioleiomyomatosis histologic score. Am J Surg Pathol 25(4):479-484
15. Ho TB, Hull JH, Hughes NC (2006) An 86-year-old female with lymphangioleiomyomatosis. Eur Respir J 28(5):1065
16. Moses MA, Harper J, Folkman J (2006) Doxycycline treatment for lymphangioleiomyomatosis with urinary monitoring for MMPs. N Engl J Med 354(24):2621-2622
17. Kitaichi M, Nishimura K, Itoh H, Izumi T (1995) Pulmonary lymphangioleiomyomatosis: a report of 46 patients including a clinicopathologic study of prognostic factors. Am J Respir Crit Care Med 151(2 Pt 1):527-533
18. Taveira-DaSilva AM, Steagall WK, Rabel A et al (2009) Reversible airflow obstruction in lymphangioleiomyomatosis. Chest 136(6):1596-1603
19. Taveira-DaSilva AM, Stylianou MP, Hedin CJ et al (2004) Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone. Chest 126(6):1867-1874
20. Hayashida M, Seyama K, Inoue Y et al (2007) The epidemiology of lymphangioleiomyomatosis in Japan: a nationwide cross-sectional study of presenting features and prognostic factors. Respirology 12(4):523-530
21. Steagall WK, Glasgow CG, Hathaway OM et al (2007) Genetic and morphologic determinants of pneumothorax in lymphangioleiomyomatosis. Am J Physiol Lung Cell Mol Physiol 293(3):L800-L808
22. Young LR, Almoosa KF, Pollock-Barziv S et al (2006) Patient perspectives on management of pneumothorax in lymphangioleiomyomatosis. Chest 129(5):1267-1273
23. Kinder BW, Sherman AC, Young LR et al (2010) Predictors for clinical trial participation in the rare lung disease lymphangioleiomyomatosis. Respir Med 104(4):578-583
24. Vittinghoff E, Glidden DV, Shiboski SC, McCulloch CE (2005) Regression methods in biostatistics: linear, logistic, survival, and repeated measures models, 1st edn. Springer Science and Business Media, New York
25. Cohen MM, Freyer AM, Johnson SR (2009) Pregnancy experiences among women with lymphangioleiomyomatosis. Respir Med 103(5):766-772
26. Celli BR, Cote CG, Marin JM et al (2004) The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 350(10):1005-1012